It used to be simple – or at least relatively straightforward. Big Pharma relied on ‘blockbuster’ drugs to provide profits and financial support for R&D. Then biotech became the ‘next big thing’ with small start-up companies, often spin-outs from university research and funded by venture capitalists. Big Pharma took advantage of this, in many cases, first through collaboration and then acquisition to add products to their portfolios and expertise.
All the latest mergers and acquisitions, major projects and investments throughout the industry.Read the latest business digest
Get your product noticed. Let C&I give it the profile it deserves. Contact Genevieve Kanowski on +49 6201606 638 or by email firstname.lastname@example.org to get into the next Supply Line.